Financials

News Discussions Technicals Forecast Seasonals

1541 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to IMMUNEONCO BIOPHARMACEUTICALS (SHAN operating, investing, and financing activities

1541 free cash flow for H1 24 is -137.23 M HKD. For 2023, 1541 free cash flow was -398.85 M HKD and operating cash flow was -395.88 M HKD.

‪0.00‬

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: HKD

TTM

YoY growth

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—